New Software Integrates with Leading Cryo-EM Solutions to Speed Data Collection for $1.6 Trillion
Pharma Industry Research
CLEVELAND, Ohio, July 30, 2024 – Health Technology Innovations (HTI), a leader in AI automation in pharma research, announced the delivery of its CryoFAST AI Data Automation Software today at the Microscopy and Microanalysis conference. CryoFAST has been developed in collaboration with leading research institutes and solutions providers to automate the time consuming and human intensive sample screening and data collection steps in the Cryo-EM workflow, a vital early step in structure determination. The software is estimated to drive down scientist time spent in sample screening from six hours to five minutes while cutting scope data collection time in half representing over 50% of estimated annual costs for labs implementing the AI tool.
“AI is transforming industries, and the pharmaceutical arena is one of the first adopters of this powerful technology to introduce cost efficiency and speed for breakthrough results,” said Tuan Phamdo, CEO and Founder of HTI. “We’ve delivered CryoFAST to the market to help labs accelerate structure-based drug discovery allowing scientists to quickly and cost effectively move through early-stage analysis freeing up time for inspection and discovery. Collaborations with industry leaders including Gatan, JEOL, and Thermo Fischer Scientific have hardened the solution which is now ready for broad deployments in labs.”
CryoFAST’s multi-grid functionality enables the software to deliver seamlessly automated grid swapping, screening up to twelve grids without manual intervention and delivers multi-shot imaging increasing data throughput by 4X vs traditional solutions. The easy-to-use GUI creates opportunity for rapid deployment into labs while delivering key tools for data management. Labs interested in trialing CryoFAST can engage HTI engineering teams for a thirty-day complimentary license by contacting info@hti.ai. CryoFAST reached 1.0 based on extensive collaboration with the industry. The 1.0 milestone could not have happened without grants from the National Science Foundation and Oregon Business Coalition.
“Delivering solutions that speed data collection helps pharma researchers identify promising drugs faster and more efficiently.” Said Jacob Brink, PhD, TEM Product Manager Life Sciences at JEOL. “We were delighted to work with HTI on the development and integration of CryoFAST into our CryoARM solution and look forward to customers leveraging this powerful tool in their Cryo applications.” “We’ve worked closely with HTI on the foundational value of AI acceleration for Cryo-EM workloads.” said Craig Yoshiaka, PhD, Co-Director of the Northwest Cryo-EM Center at Oregon Health Sciences University. “Considering user challenges with the current Cryo-EM process, HTI has delivered a solution that will unleash scientific advancement while helping to keep costs within tight research budgets. This is a major win for the industry and for scientific advancement.”
The news comes at the industry’s premier microscopy event, Microscopy and Microanalysis, where HTI will be featuring demonstrations of CryoFAST working with leading scope solutions providers and delivering multiple sessions within the conference agenda. Delivering CryoFAST 1.0 at the conference enables HTI to demonstrate its technology in industry booths to customers, helping to accelerate trials and deployments in the months ahead.
About HTI:
HTI is a leading innovator in delivering AI automation and acceleration to the pharmaceutical industry. Founded in 2019, HTI’s leadership team combines deep knowledge of the confluence of drug research, artificial intelligence, and computing innovation to deliver tools that deliver value directly to drug research teams and scale across a $1.6 trillion dollar industry. HTI is led by founder and CEO Tuan Phamdo, a seasoned tech industry leader with decades of experience at Intel, working with the technology industry to deliver disruptive innovation to customers. HTI’s advisors are leaders in their respective fields with collective experience across healthcare, pharmaceutical, research, and technology arenas. HTI is a grant recipient of the National Science Foundation as well as Oregon Business.